Home > Insider Trading > Filing (0000899243-18-008349)

Filing Details

Accession Number:: 0000899243-18-008349
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-03-22 17:33:28
Reporting Period:: 2018-03-20

Accepted Time:: 2018-03-22 17:33:28
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1377121	Protagonist Therapeutics Inc	PTGX	Pharmaceutical Preparations (2834)	980505495

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1619859	L.p. X Canaan	285 Riverside Avenue, Suite 250 Westport CT 06880		No	No	Yes	No
1673228	Canaan Partners X Llc	285 Riverside Avenue, Suite 250 Westport CT 06880		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2018-03-20	17,060	$20.61	2,402,675	No	4	S	Direct
Common Stock	Disposition	2018-03-21	17,699	$20.61	2,384,976	No	4	S	Direct
Common Stock	Disposition	2018-03-22	4,759	$20.62	2,380,217	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.50 - $20.84, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
These shares are held directly by Canaan X L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners X LLC ("Canaan X", and together with the Canaan Fund, the "Canaan Entities"), and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.50 - $20.79, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.50 - $20.87, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.